SLE is a chronic inflammatory disease that affects the kidneys in about 50% of patients.
Lupus nephritis is a major risk factor for overall morbidity and mortality in SLE, and despite
potent anti-inflammatory and immunosuppressive therapies still ends in CKD or ESRD for
too many patients. This review highlights recent updates in our understanding of disease
epidemiology, genetics, pathogenesis, and treatment in an effort to establish a framework for
lupus nephritis management that is patient-specific and oriented toward maintaining long …